Thermo Fisher Scientific Inc. (TMO) Announces the Opening of Cryo-Electron Microscopy Drug Discovery Center in South San Francisco

Core Insights - Thermo Fisher Scientific Inc. (NYSE:TMO) is recognized as a consistently growing stock in the market [1] Group 1: New Developments - The company announced the opening of its Cryo-Electron Microscopy (cryo-EM) Drug Discovery Center in South San Francisco, aimed at providing biotechnology and pharmaceutical innovators with advanced cryo-EM technologies [2] - The new center facilitates direct access to cryo-EM innovation and scientific expertise, significantly lowering barriers to adoption for pharmaceutical companies [3] Group 2: Benefits of Cryo-EM - Cryo-EM technology is expected to expand the range of therapeutic targets and advanced therapies, enabling faster drug development for pharmaceutical companies [3] - Structure-guided drugs developed using cryo-EM have over twice the rate of clinical success, with half the preclinical time and cost compared to industry standards [3] Group 3: Company Overview - Thermo Fisher Scientific Inc. provides a wide range of analytical instruments, reagents, equipment, software, and services for analysis, research, diagnostics, and discovery, operating through various segments including Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Diagnostics [5]